Navigation Links
BioMed Realty Trust's Center for Life Science Boston Now 91% Leased

SAN DIEGO, Jan. 20 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) announced today the signing of a new lease at the Center for Life Science | Boston with Kowa Company, Ltd., one of the largest privately owned companies in Japan. Kowa has agreed to lease the 17th floor, which provides approximately 24,400 square feet of laboratory and office space. As a result of this transaction, along with the recently announced lease expansion with Children's Hospital Boston, the Center for Life Science | Boston is now approximately 91% leased.

Founded in 1894, Kowa is ranked as Japan's fifth largest trading company and includes four operating divisions: Pharmaceutical, Electronics & Optics, Textile, and Non-Textile (General Merchandise).

"We are delighted to be part of the Center for Life Science | Boston, one of the pre-eminent research facilities in the world," said Yoshihiro Miwa, President and Chief Executive Officer of Kowa. "This state-of-the-art, high-rise laboratory building places Kowa in the center of the Longwood Medical Area of Boston, which we expect will enhance our collaborative research efforts in cardiovascular diseases with world-renowned medical research institutions."

Alan D. Gold, Chairman and Chief Executive Officer of BioMed, commented,

"We welcome Kowa to BioMed's premier tenant roster at the Center for Life Science | Boston. We are thrilled that a company of Kowa's stature has demonstrated the private sector's continued demand for high quality laboratory space in the Longwood Medical Area of Boston, the hub of research collaboration and technology transfer between the life science community and the Harvard-affiliated teaching hospitals. We look forward to building a long-lasting relationship with Kowa by providing an exceptional research environment at the Center for Life Science | Boston."

With the signing of the lease with Kowa, BioMed's three development properties are approximately 80% leased.

About the Center for Life Science | Boston

The Center for Life Science | Boston is a 700,000+ square foot research center that includes laboratory and office space in the heart of Boston's Longwood Medical Area surrounded by world-class life science research institutions, hospitals and bio/pharma companies, including Harvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Merck Research Laboratories Boston. The building has received Gold status pre-certification by the Leadership in Energy and Environmental Design (LEED(R)) of the U.S. Green Building Council.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 69 properties, representing 112 buildings with approximately 10.4 million rentable square feet, including approximately 1.4 million square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at

About KOWA Company, Ltd.

Kowa Company, Ltd. started operations as a cotton wholesaler in Nagoya in 1894 and has currently grown into a multinational Japanese company comprised of approximately 50 affiliated companies. Kowa actively engages in a broad spectrum of businesses and products ranging from textile goods through machinery to building materials and chemical products. Kowa also manufactures and sells many innovative and valuable products including pharmaceutical and OTC products, consumer healthcare products, electro-optical apparatus and information and communication systems. In its pharmaceutical business, Kowa is responsible for sales and marketing of innovative drugs and focuses on promoting cardiovascular drugs, such as a treatment drug for hypercholesterolemia and hypertension through its owned subsidiary, Kowa Pharmaceutical Co. Ltd. In addition, Kowa has focused on lifestyle diseases (arteriosclerosis, kidney disorder and diabetes) as a main strategic therapeutic area for research and development. Kowa is also responsible for sales and marketing of OTC and consumer healthcare products through its other wholly owned subsidiary, Kowa Shinyaku Co. Ltd. Kowa has paid-in capital of 3,840 million yen, annual sales of 221.4 billion yen (Consolidated in FY2007), and a total of 4,432 worldwide employees as of the end of March 2008 (consolidated). For additional information, please see

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioMed Realty Trust Announces Tax Treatment of 2008 Distributions
2. Alpine Biomed Acquires Stellate to Create New Leader in Neurology Diagnostics Market
3. BioMedical Enterprises, Inc. (BME) Announces the Appointment of Kenneth I. Moch as President and Chief Executive Officer
4. Collexis BiomedExperts Hits 80,000 Registered Users Within the First Year!
5. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
6. Stem Cells Poised to Grow Organs for Transplant : Zannos Grekos, MD Presents Clinical Data of Research with Adult Stem Cells to Physicians at International Regenerative Biomedicine Conference
7. Response Biomedical Corporation Announces Change of Executives
8. Launches Doctor-Driven Biomedical Autism Treatment Website
9. LA BioMed researchers among Southern California Super Doctors
10. ASH Holds a Special Symposium to Interest High School Students in Biomedical Research
11. ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... As ... Water For Empowerment ™ attracts volunteers together who want to combine talents and ... as key stakeholders in the process. The non-profit launched its first major fundraiser ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the perfect dish and pleasing the palates of attendees is of the utmost ... dish to a seasonal get-together, give these recipes a try this holiday season. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional and ... of traditional and far-infrared saunas. , For traditional saunas, Finnleo is offering ... Finnish sauna wood, and Finnleo uses only European Grade A Nordic White Spruce from ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... companies, has been recognized once again for its stellar workplace culture with the ... Work.” , Medical Solutions’ Cincinnati office was named a finalist in ...
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... ... launched offering factory direct sauna parts and accessories. , Sauna accessories help ... of the bather’s style and personality. From basic styles for the purist looking ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... 25, 2015  The American Academy of Pediatrics ... and the March of Dimes cheered today,s signature ... Infants Act of 2015 (S.799), which takes ... born exposed to drugs, such as opioids, and ... all three organizations have worked together leading advocacy ...
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
Breaking Medicine Technology: